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High frequency of functionally active Melan-A specific T cells in a 
patient with progressive immunoproteasome-deficient melanoma
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Tumor-reactive T cells play an important role in cancer
immuno-surveillance. Applying the multimer technology,
we report here an unexpected high frequency of Melan-A-
specific CTL in a melanoma patient with progressive
lymph node (LN) metastases, consisting of 18% and
12.8% of total peripheral blood and tumor-infiltrating
CD8+ T cells, respectively. Melan-A-specific CTL revealed a
high cytotoxic activity against allogeneic Melan-A-express-
ing target cells but failed to kill the autologous tumor
cells. Loading of the tumor cells with Melan-A peptide
reversed the resistance to killing, suggesting impaired
function of the MHC class I Ag processing and presenta-
tion pathway. Mutations and/or down-regulation of the
MHC class I heavy chain, the antigenic peptide TAP, and
tapasin could be excluded. However, RT-PCR and immu-
nohistochemical analysis revealed a deficiency of the
immunoproteasomes low molecular weight protein
(LMP)2 and LMP7 in the primary tumor cells, that affects
the quantity and quality of generated T cell epitopes and
might explain the resistance to killing. Overall, this is the
first report of an extremely high frequency of tumor-spe-
cific CTL that exhibit competent T cell effector functions,
but fail to lyse the autologous tumor cells. Immunothera-
peutic approaches should not only focus on the induction
of a robust anti-tumor immune response, but also have to
target tumor immune escape mechanisms.
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